PTO/SB/08 (2/92) Sheet 1 of 4

OIPE OF		
PTO-1449 PTO-1449	Docket No. GZ 2063.10	Appl. No. 09/920,4
INFORMATION DISCLOSURE	Applicant(s) Charl	es A. NICOLETTE
STATEMENT	Fill - Poles August 1 2001	Group Art Unit: 16

U.S. PATENT DOCUMENTS

Filing Date: August 1, 2001

Examiner	Ref.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
Initials	No.	07/28/87	4,683,195	Mullis et al.	_		
W S	2	07/28/87	4,683,202	Mullis			
MO	3.	06/28/88	4,754,065	Levenson et al.		 	
NIO	4.	01/24/89	4,800,159	Mullis et al.		-	
, MA	5.	08/08/95	5,440,013	Kahn Heber-Katz et al.			
	6	11/17/98	5,837,249	Lienel-Kar et al.			

FOREIGN PATENT DOCUMENTS

					Class	Subclass	Tran	slation
Examiner	Ref.	Date	Document No.	Name	Class	Jubilass	YES	NO
Initials	No.	1						
Mad		08/23/95	0 668 350 A1	Nobel	+			
MAD	8.	08/01/96	WO 96/23060	Cohen et al.		1	J	<u> </u>

OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

Group Art Unit: 1644

		(including author, title, date, partition, bases, order)
Examiner	Ref.	Title
Initials	No.	this of functional consistration with the apparent affinity
	9.	Al-Ramadi, B.K. et al. (1992) "Lack of strict correlation of functional sensitization with the apparent affinity
w		
1	10.	of MHC/peptide complexes for the TCR J. Illimunol. 135(2):302 3131 Altman, J.D. et al. (1996) "Phenotypic analysis of antigen-specific T lymphocytes" Science 274(5284):94-
١	10.	Author, v.S. St. Lin (1997)
NUO		96. Bakker, A.B.H. et al. (1997) "Analogues of CTL Epitopes with Improved MHC Class-I Binding Capacity Bakker, A.B.H. et al. (1997) "Analogues of CTL Epitopes with Improved MHC Class-I Binding Capacity Bakker, A.B.H. et al. (1997) "Analogues of CTL Epitopes" Int. J. Cancer 70:302-309.
		Bakker, A.B.H. et al. (1997) Arialogues of O'Lephone" Int. J. Cancer 70:302-309.
1 Ww/	1)	
	12.	Elicit Anti-Melanoma CTL Recognizing the Wild Type Epilope Miles States and CTL repertoires extend to chimpanzees" J. Bertoni, R. et al. (1998) "Human class I supertypes and CTL repertoires extend to chimpanzees" J.
hen		Immunol. 161:4447-4455.
150	13.	Immunol. 161:4447-4455. Boczkowski, D. et al. (August, 1996) "Dendritic cells pulsed with RNA are potent antigen-presenting cells
N.	1 .2.	
NIC	/	
1	14.	Bordignon, C. et al. (September, 1989) "Retroviral vector-mediated might structurely adenosine deaminase (ADA) in hematopoietic long-term cultures of ADA-deficient marrow cells" PNAS
My		adenosine deaminase (ADA) in hematopolesic long term obtained
	1	USA 86:6748-6752.
1 20	15.	USA 86:6748-6752. Carter, B.J. (1992) "Adeno-associated virus vectors" Curr. Op. Biotechnol. 3:533-539. Carter, B.J. (1992) "Adeno-associated virus vectors" Curr. Op. Biotechnol. 3:533-539.
	16.	Caruso A et al. (1997) "Flow cytometric analysis of activation markets on summaries."
NUC	10.	correlation with cell proliferation" Cytometry 27:71-76.
100	4	4000) *Production of hilman diucocelebiosidase in times and
. ^	17.	Correll, P.H. et al. (November, 1999) Froduction progenitor cells" PNAS USA 86:8912-8916.
	1	Correll, P.H. et al. (November, 1969) Production of many production of

DATE CONSIDERED: EXAMINER:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

(use several sheets if necessary)



PTO/SB/08(1292) Sheet 2 qf 4

Form PT)-144	BADEMAN	Docket No. GZ 2063.10	Appl. No. 09/920,480	
		HALL	Applicant(s)		
INF		ATION DISCLOSURE STATEMENT	Charles A. NICOLETTE		
	(use se	veral sheets if necessary)	Filing Date: August 1, 2001	Group Art Unit: 1644	
MO	18.	Coulie, P.G. (June, 1997) "Huma cancer vaccines?" <i>Molec. Med. T</i>	n tumour antigens recognized by T cells oday 3:261-268.	s: new perspectives for anti-	
1	19.	Culver, K. et.al. (April, 1991) "Lyr PNAS USA 88:3155-3159.	mphocytes as cellular vehicles for gene	therapy in mouse and man*	
MO	20.	Dharanipragada, R. et al. (1992) synthesis of unusual amino acids	"The absolute configuration of an intern" " Acta. Cryst. C48:1239-1241.	nediate in the asymmetric	
W	21.	Dharanipragada, R. et al. (1993) Res. 42 (1):68-77.	"Synthetic linear and cyclic glucagon an	tagonists" Int. J. Peptide Protein	
MD	22.	DiMaio, J. et al. (1989) "Synthesis Perkin Trans. 1(9):1687-1689.	s of chiral piperazin-2-ones as model pe	eptidomimetics" J. Chem. Soc.	
	23.		Competition inhibition of cytotoxic T-lym		
. Ms		sensitive method to identify candidate CTL epitopes than induction of antibody-detected MHC class I stabilization" <i>Immunol. Lett.</i> 47:1-8.			
MO	24.	Ferguson, M.A.J. et al. (1988) "Cell-surface anchoring of proteins via glycosyl-phosphatidylinositol structures" <i>Ann. Rev. Biochem.</i> 57 :285-320.			
· ME	25 .	producing cells" J. Immunol. Meth			
. WD	26.		substituted γ-lactam rings as conformati partic acid or norleucine" <i>J. Org. Chem.</i>		
m	27.	Hruby, V.J. (1982) "Conformation groups" <i>Life Sciences</i> 31 (3):189-	al restrictions of biologically active pept 199.	ides via amino acid side chain	
WED	28.		ng approaches in the molecular design on the molecular design of the sign of t		
	29.	Isakov, N. et al. (January, 1995) "	ZAP-70 binding specificity to T cell rece	eptor tyrosine-based activation	
NO		affinity" J. Exp. Med. 181:375-380			
his	30.	Jones, R.C.F., et al. (1988) "Amid Tetrahedron Lett. 29(31)3853-38	de bond isosteres: imidazolines in pseu 56.	dopeptide chemistry"	
My	31.	Kahn, M. et al. (1989) "The incorp synthesis" <i>Tetrahedron Lett.</i> 30(poration of β-turn prosthetic units into m 18):2317-2320.	errifield solid phase peptide	
Mus	32.	Karlsson, S. et al. (1986) "Stable using adenoviral vectors" The EM	gene transfer and tissue-specific expres IBO J. 5(9):2377-2385.	ssion of a human globin gene	
W	33.	Kazmierski, W. M. et al. (1991) "Asymmetric synthesis of topographically constrained amino acids: synthesis of the optically pure isomers of α,β-dimethyl-phenylalanine and α,β-dimethyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid" <i>Tetrahedron Lett.</i> 32 (41):5769-5772.			
MO	34.	Kazmierski, W.M. et al. (1991) "T	opographic design of peptide neurotran conformation and dynamics to bioactivit	smitters and hormones on stable	
	35.	· · · · · · · · · · · · · · · · · · ·	lly restricted cyclic nonapeptides derive	- 1	
mo		amino-2-piperidone-6-carboxylic a Org. Chem. 50 :5834-5838.	acid (LL-Acp), a potent β-turn-inducing c	lipeptide analogue" (1985) <i>J.</i>	
in	36.		national analysis of peptide-functionaliz	ed diacylaminoepindolidiones ¹H	
EXAMINER		MD	DATE CONSIDERED:	3/10/00	
EXAMINER: I considered. Ir	nitial if ci	tation considered, whether or not the citation copy of this form with next communication	on conforms with MPEP 609. Draw a line through to applicant.	h the citation if not in conformance and not	

	7 5 2002		Þ	TO/SE/08 (2/95)
Form PTO-1449		Docket No. GZ 2063.10	Appl. No. 09/920,480	O 4 NTER
	The state of the s	A college (A)		
	TION DICCLOSUPE	Applicant(s) Charles A.	NICOLETTE	1600/2900
INFORMA	TION DISCLOSURE			72
	I A I EIVIEIN I	Filing Date: August 1, 2001	Group Art Unit: 1644	8
/una 501	veral sheets if necessary)			
		nation" Tetrahedron Lett. 29(40):5081-	5082.	4 6 dioza
37.				y-1, 0-ulaza-
37.	cyclodeca-2, 7-dione The dilact	iam of L-α, γ-diaminobutyric acid and c)-glutamic acid: A p-turi	Lemplace
ha.C	Tetrahedron Lett. 29(40):5057-	5060.	5 and any 10 this trick	-lo-12 8 0 ^{4,8} 1-
38.			-9-Carboxy-10-una-uncyc	-I -(Ala)OR
1 122 N 1	(n=1 to 4) and α-temp -L-Ala-L	-bue-ras(seoc)-r-ras(s-poc)-in into a	ludies of templates for	
	formation" Tetrahedron Lett. 29	3(39):4935-4938.	dary structures of polyp	eptides. 4.
39.	Kemp, D.S. et al. (1989) "Amii	no acid derivatives that stabilize secon mino)-3-cyano-6-azabicyclo[3.2.1]oct-	Renes (ben derivatives)	as y-turn
	Practical synthesis of 4-(alkyla	mino)-3-cyano-o-azabicyciolo:2: 1100: 1		
· M	templates" J. Org. Chem. 54:1	hort communications: A simple technication of the communication of the c	que for the rescue of ea	rly region I
40.				
My	mutation into infectious numar	adenovirus type 5" Virology 163:614- pproaches to the chemical synthesis o	f peptides" Recent Prog	ress in
41.				
my	Hormone Res. 23:451-482.	esis and angiotensin converting enzyn	ne inhibitory activity of 1	,2,3,4-
ABSTRACT42.	Miyake, A. et al. (1984) "Synth	esis and angiotensin contenting only. exylic acid derivatives" J. Takeda Res.	Labs. 43(3/4):53-76.	
ONLYND		19) #Daaiatanaa 10 BUMBN 101111111111111111	TIELICA ALLOS I HILOSTICI.	of SCID mice
43.	Mosier, D.E. et al. (March, 195	lood leukocytes from donors vaccinate	ed with vaccinia gp160 a	and
1. 1. 1.				
WW)	Murayaka M (1992) "Use of	adeno-associated virus as a general tra	ansduction vector for ma	ammalian
44.				
45.	Nagai II et al (1985) "Synthe	esis of a bicyclic dipeptide with the sha	pe of β-turn central part	:" Tetrahedron
MA 45.				
46.	this Catal (Cohmical 1002) "Soluble proteins delivered to dendrit	ic cells via pH-sensitive	liposomes
1 h A ()				
47.	Olson, G.L. et al. (1990) "Des	ign and synthesis of a protein β-turn m	ilmetic" J. Am. Chem. S	00, 112.323
1 11.01	I			
48.	Deslie D et al (January 199	6) "Murine dendritic cells loaded in vitr	o Mitu solnole brotein bi	and of totolio
$ W\rangle$	Thronbooutee against tumor	antigen in vivo" J. Exp. Med. 103.317	JZZ	
M 49.			J-33 I.	C class I
50.	Parker K.C. et al. (1992) "Se	quence motifs important for peptide of	numy to the number with	
1 1				
51.	Parker, K.C. et al. (1995) "Pe	eptide Binding to MHC Class 1 Molecul	ca. Implications for Am	.g
	1	1.9 A E 7		
N 1 (52.	Parkhurst, M.R. et al. (1996)	"Improved induction of melanoma-rea	s" J. Immunol. 157:2539	J-2548.
'44')		odified at HLA-A*0201-binding residues 2) "An approach for the analysis of rela	Dae and many with	
53.				
MO	autologous marrow transplar	tation using retrovitus-mediated gensiliber, 1994) "Induction in vitro of primar	v cytotoxic T-lymphocyto	e responses
14.	Rouse, R.J.D. et al. (Septem	implex virus proteins" J. Virol. 68(9):56	85-5689.	
1000	with DNA encoding herpes s	milibies and biorouse as such as follower		

	DATE CONSIDERED: 3/8/54
EXAMPLES: Initial if citation considered, whether or not the citation conforms	with MPEP 609. Draw a line through the citation if not in conformance and not
considered. Include a copy of this form with next communication to applicant.	

2 5 700 25		PT	O/SB/08 (2/92) Sheet 4 of 4
A RES	Docket No. GZ 2063.10	Appl. No. 09/920,480	ECY ,
ON DISCLOSURE ATEMENT	Applicant(s) Chai	d s A. NICOLETTE	CENTE

				
Form PTO-144	19	Docket No. GZ 2063.10	Appl. No. 09/920,480	ECH
	IATION DISCLOSURE STATEMENT	Applicant(s) Cha	art s.A. NICOLETTE	HCENTER 1600/2900
(use s	everal sheets if necessary)	Filing Date: August 1, 2001	Group Art Unit: 1644	7 1600
55.	Salazar, E. et al. (2000) "Agonist carcinoembryonic antigen stimula phosphorylation more efficiently the state of the stat	ites production of TC1-type cyt	okines and increases tyrosine	012900
56.	Samanen, J. et al. (1990) "5,5-dir restricted conformation" Int. J. Pe			with
M) 57.	Schlesinger, S. et al. (1999) "Alph 10(5):434-439.			
M 58.	Sette, A. et al. (1994) "The relation cytotoxic T cell epitopes" J. Immu	nol. 153 (12):5586-5592.		
144) 59.	Shirai, M. et al. (1995) "CTL response of the predict epitopes for CTL of human	ns carrying HLA-A2.1" <i>J. Immu</i>	inol. 154:2733-2742.	• •
·HW 60.	Stuber, G. et al. (1995) "HLA-A0201 and HLA-B7 binding peptides in the EBV-encoded EBNA-1, EBNA-2 and BZLF-1 proteins detected in the MHC class 1 stabilization assay. Low proportion of binding motifs for several HLA class 1 alleles in EBNA-1" Int. Immunol. 7(4):653-663.			
U ₁ ∩ 61.	Tan, L. et al. (1997) "An improved MHC molecules" J. Immunol. Met	assembly assay for peptide b		(*class I
62.	Tanguay, S. et al. (1994) "Direct of individual cytokine-secreting cells	comparison of ELISPOT and E " Lymphokine Cytokine Res. 1	3(4):259-263.	
63.	Valmori, D. et al. (2000) "Induction a melan-A peptide analogue" J. Ir	mmunol. 164(2):1125-1131.	-	·
· 40 64.	van der Burg, S.H. et al. (1996) "I the MHC-peptide complex stabilit			epends on
M) 65.	Ware, C.F. et al. (1983) "Recogni human cytotoxic T lymphocyte line	e" J. Immunol. 131(3):1312-13	17.	
M 66.	Wilchek, M. et al. (1988) "The avi 32.	· · · · · · · · · · · · · · · · · · ·		
₩D 67.	Ying, H. et al. (July 19, 1999) "Ca. 827.	ncer therapy using a self-replic	eating RNA vaccine" Nat. Med. 5	5(7):823-
68.	Zabrocki, J.et al. (1988) "Conform cis amide bond" J. Am. Chem. Sc	i. 110 :5875-5880.		
69.	Zechel, C. et al. (1991) "Synthetic 38(2):131-138.			
(LAC) 70.	Zweerink, H.J. et al. (March 1, 19) cytotoxic T lymphocytes in transpo	93) "Presentation of endogenoort deletion mutant T2 cells" <i>J.</i>	us peptides to MHC class I-rest Immunol. 150(5):1763-1771.	ricted

		
EXAMINER		DATE CONSIDERED: OIM ON 1
		DATE CONSIDERED. SIN ASTE
EYAMINER: I	itial if citation considered subother as not the citation conforms	with MDED COO. Down time the way the state of the state o
EXCHINITEEN. II	ide in Cladon Considered, Whether of not the citation conforms	with MPEP 609. Draw a line through the citation of not in conformance and not
considered. In	clude a copy of this form with next communication to applicant.	

PTO/SB/08A (10-01)
Approved for Chrough 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

± 1644

Substitute for forms 449A-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of

Complete if Known		
Application Number	09/920,480	
Filing Date	August 1, 2001	
First Named Inventor	Charles A NICOLETTE	
Art Unit	1644	
Examiner Name	Not Yet Assigned	
Attorney Docket Number	GZ 2063.10	

	U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No. ¹	Document Number Number – Kind Code ² (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
MO	1	US-5,695,937	12/9/97	Kinzler et al.	Dros
MI	2	US-5,869,445	2/9/99	Cheever, et al.	DECEIVE
1	3	US-6,028,059	2/22/00	Curiel, et al.	-11/
N	, 4	US-5,844,075 (*)	12/1/98	Kawakami et al.	AUG 0 8 2002
					TECH CENTER 1600
					1000/2

		FOREIGN PAT	ENT DOCU	MENTS		
Examiner Initials*	aminer Cite Foreign Patent Document		Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	5	FR 2,757,169	6/19/98	Institute Nat'l de la Sante et de la Recherche Medical InsermEstabliss Public a Caract Scient et Tech		>
MD	6	WO 99/02183	1/21/99	CTL Immunotherapies Corp.		
140	7	WO 00/20457	4/13/0	Genzyme Corp.	<u> </u>	1
M	8	WO 97/35035 (*)	3/20/97	Genzyme Corp.		

Examiner's		Date	_1 /	
Signature	Marian (1)	Considered	21 18104 I	
J.g	VI Course 10			

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08B (10-01)


Approved for through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
at of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known PADE A 09/920,480 **Application Number** August 1, 2001 Filing Date INFORMATION DISCLOSURE Charles A. NICOLETTE First Named Inventor STATEMENT BY APPLICANT 1644 Art Unit **Not Yet Assigned Examiner Name** (use as many sheets as necessary) GZ 2063.10 Attorney Docket Number of 2

Sheet

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		$\left\{ \right.$
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal,	T ²	١
Initials*	No.1	serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published		1
	1	ALEXANDER-MILLER et al. "Selective expansion of high-or low-avidity cytotoxic T lymphocytes and		1
	-			4
	2_	BLOOM et al. "Identification of tyrosine-related protein 2 as a tumor rejection antigen for the B16		1
		melanoma" ./ Fxp Med (1997), 185(3):403 (*)		₽
	3	BORCHARDT et al., "Small molecule-dependent genetic selection in stochastic nanodroplets as a		F
		means of detecting protein-ligand interactions on a large scale" Chem. Biol. (1997) 4(12):901-908 (1)	<u> </u>	#
	4	BOUCHARD et al., "Molecular characterization of a human tyresinase-related-protein-2 cDNA.	<u>. </u>	þ
~	 		<u> </u>	7007
	5	COCKLE S.M. et al. "Thyrotrophin-releasing hormone-related polypeptides in rabbit prostate and	5	70
XXXX	1	semen are different from those in rabbit hypothalamus" J. Endocrinology (1989) 120: 31-36	Ē	1
7 1	_6_	COLACO "Why are dendritic cells central to cancer immunotherapy?" Mol. Med. (January 1999)	<u> </u>	╀
	<u>. </u>	Today:14-17 (*)		╛
	7	FISK, B. et al. "Changes in an HER-2 peptide upregulating HLA-A2 expression affect both	1	1
. ^	\ ′	conformational epitopes and CTL recognition: Implications for Optimization of antigen presentation		
NU	İ	and tumor-specific CTL induction" Immonol. (1996) 18(4):197-209	<u>L_</u>	↓
7- 1	 	FORBES, J.F. "The incidence of breast cancer: The global burden, public health considerations"		
Mn	8	Seminars in Oncology (1997) 24(1), Suppl. 1. pp. S1-20-S1-35	L	_
	9	GISH et al., "Identification of protein coding regions by datebase similarity search" Nature Genetics		4
		(1993) 3:266-273 (*)		_
<u> </u>	10	GREENLEE, R.T. et al. "Cancer Statistics, 2001" . CA Cancer J Clin (2001) 51(1):15-36	<u> </u>	
1 m	11	KAWAKAMI et al., "Identification of a human melanoma antigen recognized by tumor-infiltrating		
MARIA	} ''	lymphocytes associated with in vivo tumor rejection" PNAS USA (1994) 91:6458-6462 (*)	<u> </u>	_
1.0	12	KAWAKAMI, Y. et al., "Cloning of the gene coding for a shared human melanoma antigen recognized]	1
I KWA	'2	by autologous T cells infiltrating into tumor" PNAS USA (1994) 91(9):3515-3519 (*)		
-	13	KUHNS, J.J. et al. "Poor Binding of a HER-2/neu Eiptope (GP2) to HLA-A2.1 is due to a lack of	}	
M) 'S	interactions with the center of the peptide" J. Biol. Chem. (1999) 274:36422-36427	<u> </u>	_
	14	LINDAUER et al., "The molecular basis of cancer immunotherapy by cytotoxic T lymphocytes" J. Mol.	1	1
MA) 'T	Med. (1998) 76:32-47 (*)		4
	15	LOCKHART, D.J. and E.A. WINZELER "Genomics, gene expression and DNA arrays" Nature (2000)	1	1
Mo	'3	405:827-836	1_	╛
*	16	RIES, L.A. et al. "The annual report to the nation on the status of cancer, 1973-1997, with a special	}	
M	⊅ "	section on colorectal cancer" Cancer (2000) 88(10):2398-2424	1	╛
	17	RONGEUN, Y, et al. "Identification of new HER2/neu-derived peptide epitopes that can elicit specific		1
K	\ ''	CTL against autologous and allogeneic carcinomas and melanomas" J. Immunol. (1999) 163:1037-	ļ	-
M	기	1044	↓	_
<u> </u>	18	ROSENBERG et al., "Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the	+-	4
	1 -10	treatment of patients with metastatic melanoma" Nature Med. (1998) 4(3):321-327 (*)	4_	╝
	19	SALGALLER et al., "Recognition of multiple epitopes in the human melanoma antigen gp100 by		-
_		peripheral blood lymphocytes stimulated in vitro with synthetic peptides" Cancer Res. (1995) 55:4972-	+	1
	1	4979 (*)	\perp	ᅵ
,	20	to the state of th	1	
1	20	genes" PNAS USA (1996) 93:10614-10619 (*)		
L	. **	3-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1		



		Sheet 2	of		Attorney Docket N	ber	2063.10	
<u> </u>				ART NON PATE		DOCUM	ENTS	
		OTHER	PRIOR	CARLAN LETTERS HILL	the article (when appropriate).	title of the item	(book, magazine, journal,	T ²
Examiner		include name	eium catalon	etc \ date nage(s), volume-iss	ue number(s), publisher city and	1/or country who	are published	
initials	No.	senal, sympo	Siuri, Calalog,	etc.), date, pege(c), resemble	a of an arrayed human (renomic libr	ary generated with	
VO IV E	·}\	SHEPHER	RD et al., Th	reparation and screening	2629-2633 (*)	301101111011101	ary generates man	_
- 1 7		THE PT CHE	ning syster	many prevention of colors	ectal cancer" Bulletin of t	he World H	ealth Organization	
	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS OTHER PRIOR ART – NON PATENT LITERAS), till or the stricts (when appropriate), bits of the liten (book, negatine, journal, 17 stricts, serposetine, catalog, etc.), date, people), volume-tasse number(s), publisher cly and/or country-when published stricts, serposetine, catalog, etc.), date, people), volume-tasse number(s), publisher cly and/or country-when published in the P1-dio-ring system* PPAS USA (1994) 91:2629-2633 (*). SHIKE, M. et alPrioreomics in Early Detection of Cancer* Cline. Chem. (2001) 47(10):1991-1991 (1990) 86(3):377-385 SRINIVAS, P. et al. "Protection in Early Detection of Cancer* Cline. Chem. (2001) 47(10):1991-1991 (1990) 86(3):37-385 TURECH et al. "Scritological snallysis of human human amogens." Molecular definition and implications of Mol. Med. (August 1997) Today 3(8):342-349 (*) WEI, W. et al. "Protection against mammary tumor growth by vaccination with full-length, modified human Eribes 2 Nov.* Intl. J. Cancer (1999) 81:748-754 27. ZHALE al. "Cleoning and characterization of the genes encoding the murine homologues of the human melanoma analogens MART1 and approof. J. Immunol (1997), 20(1):15-25 (*) 28. ZOGEL, U. et al. "Termination of peripheral tolerance to a Trust epitope by heterocitic antigen analogues". J. Immunol. (1998) 181(4):1705-1709 (*) FECH CENTER 1000/2000							
14.00	OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), site of the article (when appropriate), site of the laten (book, magazine, journal, 17 on the settle), symposium, catelog, etc.), date, page(s), volume-base number(s), publisher day and/or country where publisher settle, symposium, catelog, etc.), date, page(s), volume-base number(s), publisher day and/or country where publisher days and/or country generated with the B1 cloning system *PANS USA (1994) 97-2629-2633 (*) SRINIVAS, P. et al. *Proteomics in Early Detection of Cancer Clin. Chem. (2001) 47(10):1901-1911 PATENCE of at a "Sortogogical analysis of human tumor analysis. 20							
b 19/01/	OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), till of the article (when appropriate), tills of the item (box), magazine, journal, it is seed, sympostum, cutatog, etc.), due, papelly, volume-asses number(s), publisher day and/or country where published with seed, sympostum, cutatog, etc.), due, papelly, volume-asses number(s), publisher day and/or country where published with the PL dening system? PNAS USA (11994) \$17.2625-2633 (c) SHIKE, M. et al. "Printerprise provention of coherctal cancer" Bulletin of the World Health Organization (1990) 68(3):773-7365 SRINIVAS, P. et al. "Proteomics in Early Detection of Cancer" Clin. Chem. (2001) 47(10):1901-1911 TAMP Symbiotic peptide vaccione design: Systabasis, and properties of a high-density multiple antigenic papilide system? PNAS US (1998) 48:5409-5413 (c) 25 FURECH et al. "Secological analysis of human tumor antigens: Moterular definition and implications" (Mol. Med. (August 1997) Today 3(8):342-349 (c) WEI, W. et al. "Protection against mammary tumor growth by vaccination with full-length, modified human Eriba 2 DNA* Intri. Carriar (1998) 117-48-754 27 ZHAL et al. "Cloring and characterization of the genes encoding the murine homologues of the human embalogues by the characterization of the genes encoding the murine homologues of the human embalogues and properties of the summan analogues." J. Immunol. (1998) 161(4):1705-1709 (c) **RECENTER** 1600/2000** **PROTECTION** 1. Carriar 1600/2000** **PROTECTION*							
MAIN	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Induce name of the author (in CAPITAL LETTERS), tills of the addis (when appropriate), tills of the latent (book, mapsterin, journal, 17 interest in the prior of the latent (book mapsterin, journal, 17 interest interest in the latent (book mapsterin, journal, 17 interest interes							
	_25	TÜRECH	et al. "Seroi	ogical analysis of humar	tumor antigens: Molec	ular definitio	n and implications"	1
		Mol Med	(August 19	997) Todav 3(8):342-349	9 (*)			<u> </u>
A 1.0	26	WEI, W.	et al. "Prote	ection against mammary	tumor growth by vaccina	ation with fu	I-length, modified	ļ
Min		human Ei	bB-2 DNA"	' Int'l J. Cancer (1999) 8	1:748-754	ausia a bassa	the human	-
	27	ZHALeta	I. "Cloning	and characterization of t	he genes encoding the r	nume nome -25 (*)	Jiogues or the Human—	
		melanom	a antigens	MARTI and gp100 J. III	elerance to a Trell police	ne hy heter	oclitic antigen	
	28	ZUGEL,	7. 61. 31. 16	rmin <u>ation of peripheral to</u>	016121106 to a 1 cell opito 1700 (*)	pe by note		1
	<u> </u>	analogue	S J. IIIIIIIII	101. (1990) 101(4).1100-	1700 (-)		REOR	
		ļ <u>.</u>						VE
	<u> </u>	 					Aug	15
		 					- 106 0 8 26	ļ.,
	 	 					TECHA	V2_
	 	<u> </u>					- CON CENTER 100	<u>]</u>
								¥291
								1-0
								╁─
								+
	ļ	ļ						+-
	↓						<u> </u>	╁
	↓							+-
	 	 						+-
	 	 						+
	 	 						1
	 	<u> </u>						
	 	+						
	┼							
	┼							
	+	+						
	+		·.•··					
	 							
	+							\perp
	+							\downarrow
	1	\top						╁-
								4-
Evamined			/		Date	1 1		
Signature	•	1//	γ_{Λ}		Considered 2	18/18	<i>0</i> 1	

[•] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Examiner Ref. Initials No.	Form P1	O-14 ⁴	19	ON DISCLOSURE TEMENT Filing Date: August 1, 2001 U.S. PATENT DOCUMENTS The Document No. Name Class Subclass Filing Date (if application) FOREIGN PATENT DOCUMENTS The Document No. Name Class Subclass Translation YES NO OTHER DOCUMENTS (including author, title, date, pertinent pages, etc.)				
Filing Date: August 1, 2001 Group Art Unit: 1644	IN	FORM	IATION DIS	; SCLOSURE NT	Applicant(s)	Charles A. Ni	COLETTE	
U.S. PATENT DOCUMENTS Examiner Initials No. No.	16	=			Filing Date: August 1, 2001		Group Art U	nit: 1644
INFORMATION DISCLOSURE STATEMENT Filing Date: August 1, 2001 Group Art Unit: 1644 U.S. PATENT DOCUMENTS Examiner Ref. Date Document No. Name Class Subclass Filing Date (if apartariset) FOREIGN PATENT DOCUMENTS Examiner Ref. Date Document No. Name Class Subclass Translation Initials No. 11/02/95 WO 95/29193 The Government of the United States of America Disclass No. 11/02/95 WO 95/29193 The Government of the United States of America Disclass No. 11/02/95 WO 95/29193 The Government of the United States of America Disclass No. 11/02/95 WO 95/29193 The Government of the United States of America Disclass No. 11/02/95 WO 95/29193 The Government of the United States of America Disclass No. 11/02/95 WO 95/29193 The Government of the United States of America Disclass No. 11/02/95 WO 95/29193 The Government of the United States of America Disclass No. 11/02/95 WO 95/29193 The Government of the United States of America Disclass No. 11/02/95 WO 95/29193 The Government of the United States of America Disclass No. 11/02/95 WO 95/29193 The Government of the United States of America Disclass No. 11/02/95 WO 95/29193 The Government of the United States of America Disclass No. 11/02/95 WO 95/29193 The Government of the United States of America Disclass No. 11/02/95 WO 95/29193 The Government of the United States of America Disclass No. 11/02/95 WO 95/29193 The Government of the United States of America Disclass No. 11/02/95 WO 95/29193 The Government of the United States of America Disclass No. 11/02/95 WO 95/29193 The Government of the United States of America Disclass No. 11/02/95 WO 95/29193 The Government of the United States of America Disclass No. 11/02/95 WO 95/29193 The Government of the United States of America Disclass No. 11/02/95 WO 95/29193 The Government of the United States of America Disclass No. 11/02/95 WO 95/29193 The Government of the United States of America Disclass No. 11/02/95 WO 95/29193 The Government of the United States of America Disclass No. 11/02/95 WO 95/29193 The Government of the United St								
INFORMATION DISCLOSURE STATEMENT P(dos septral sheets if necessary) U.S. PATENT DOCUMENTS Examiner Initials No. FOREIGN PATENT DOCUMENTS Examiner Initials No. 7. 11/02/95 W0 95/29193 The Government of the United States of America OTHER DOCUMENTS Examiner Initials No. OTHER DOCUMENTS Examiner Initials No. OTHER DOCUMENTS Examiner Initials No. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25.								
Section Sect	Examiner Initials Examiner Initials Examiner Initials Examiner Initials Initials Examiner Initials Initials Examiner Ini	Т.				-	 	(II altorogalate)
Examiner Ref. Date Document No. Name Class Subclass Translation YES NO		FORMATION DISCLOSURE STATEMENT P(be special sheets if necessary) U.S. PATENT DOCUMENTS Ref. State Document No. Name Class Subclass Filing Date (if approximate) FOREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS Ref. Date No. 111/02/95 WO 95/29193 The Government of the United States of America OTHER DOCUMENTS Ref. Tittle No. 8. 9. 10. 11. 11. 11. 11. 11. 11. 11. 11. 11						
Examiner Ref. Date Document No. Name Class Subclass Translation YES NO			<u> </u>			Class Subclass Filing Date (if appropriate) Class Subclass Filing Date (if appropriate) NT DOCUMENTS Class Subclass Translation YES NO ernment of the tates of America Class Subclass Translation YES NO (including author, title, date, pertinent pages, etc.)		
Examiner Ref. Date Document No. Name Class Subclass Translation YES NO							1 · C,	Filing Date (if appropriate) Translation YES NO
Examiner Ref. Date Document No. Name Class Subclass Translation YES NO			L				 	(C)
Examiner Ref. Date Document No. Name Class Subclass Translation YES NO	<u></u>	6.	<u>L</u>				<u> </u>	100
Title			Date					
United States of America			14/02/05	1410 05/00400	<u> </u>			
Examiner Ref. Title	NO	7.	11/02/95	WO 95/29193				
Initials No.				10	THER DOCUMENTS			
Initials No. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25.	Examiner	Ref.	Title			(includin	g author, title, o	date, pertinent pages, etc.)
INFORMATION DISCLOSURE STATEMENT P (this serving sheets if necessary) U.S. PATENT DOCUMENTS Examiner Initials No. 7. 11/02/95 WO 95/29193 The Government of the United States of America OTHER DOCUMENTS Examiner Initials No. 10. 11. 12. 13. 14. 15. 16. 17. 11. 18. 19. 10. 11. 12. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 21. 22. 23. 24. 24. 25.								
9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24.	Examiner Initials No. 17. 11. 11. 11. 11. 11. 11. 11. 11. 11							
10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24.			,					
11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25.	INFORMATION DISTATEMEN						<u> </u>	
12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25.							· · · · · · · · · · · · · · · · · · ·	
13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24.					•			
14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25.			·					
15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25.					· · · · · · · · · · · · · · · · · · ·			
16. 17. 18. 19. 20. 21. 22. 23. 24.					·			
INFORMATION DISCLOSURE STATEMENT P(cbs seprent sheets if necessary) U.S. PATENT DOCUMENTS Examiner Initials No. FOREIGN PATENT DOCUMENTS Examiner Initials No. 7. 11/102/95 WO 95/29193 The Government of the United States of America OTHER DOCUMENTS Examiner Ref. Title Initials No. OTHER DOCUMENTS Examiner Ref. Title Initials No. 10. 11. 12. 13. 14. 15. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25.								
19. 20. 21. 22. 23. 24. 25.	INFORMATION DISCLOSURE STATEMENT Pulse several sheets if necessary) Examiner Initials No. Examiner Initials No. Examiner Initials No. Examiner Initials No. Initials No. Examiner Initials No. Initials No							
20. 21. 22. 23. 24. 25.			<u>· · · · · · · · · · · · · · · · · · · </u>					
INFORMATION DISCLOSURE STATEMENT Possible special sheets if necessary) U.S. PATENT DOCUMENTS Examiner Ref. Initials No. 7. 11/02/95 WO 95/29193 The Government of the United States of America OTHER DOCUMENTS Examiner Ref. Title Initials No. 8. 9. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 19. 20. 20. 21. 20. 21. 21. 22. 23. 24. 25.								
22. 23. 24. 25. 25.				<u> </u>		·		
23. 24. 25.	INFORMATION DISCLOSURE STATEMENT Filing Date: August 1, 2001 Group Art Unit: 1544 U.S. PATENT DOCUMENTS Examiner Initials No. 7. 11/02/95 WO 95/29193 The Government of the United States of America OTHER DOCUMENTS Examiner Ref. Initials No. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 31. 31. 44. 45. 55. 66. TOTHER DOCUMENTS Initials No. 8. 9. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25.							
24. 25.								
25.	INFOR Property P		·			•		
			· · · · · · · · · · · · · · · · · · ·				 -	
								·

EXAMINER: Mariame Dir DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and no considered. Include a copy of this form with next communication to applicant.

PTO/SB/08 (2-92)

Form DTC	1440				Docket Number 15070	22006300	Annlication N	Sheef 1 of 2
Doctart Number 197922006300 Application Number 09797373 Application Number 19792006300 Application Number 1979200 Application Number 19790 Application Number 19790 Application Number 19790 Application Number 19790 Application Number 19700	mper navigation							
	o to							
							•	/0~=
			U.S. PA	TEN	T DOCUMENT	S		20 E
	Doctor Number 159792006500 Application Number 99784917 Applicant Discrete Anicolette Filing Date February 11, 1999 Group At Unit 1681 group At U	Filing Date If Appropriate						
	<u> </u>	<u></u>						·
! 			FOREIGN	РАТ	ENT DOCUME	NTS		•
		Date	Document No.		Country	Class	Subclass	
NAO	1.	03/20/97	WO 97/35035	Nicc	lette			
•			ОТНІ	ER D	OCUMENTS	(inclus	ling author, title, D	ate, Pertinent Pages, Etc.)
		Title						
\sim	2.	lymphocyte	Miller et al., "Select es and efficacy for	ctive o	expansion of high	h-or low-av apy" <i>PNAS</i>	idity cytotox USA 93(9):4	ic T 102-4107
	3.	Bloom et a B16 melan	l., "Identification of oma" J. Exp. Med.	f tyro 185(sine-related proto 3):453 (1997).	ein 2 as a tu	mor rejection	n antigen for the
	4.	means of d	et al., "Small molec etecting protein-lig	ule-d and ii	ependent genetic nteractions on a l	selection in arge scale"	n stochastic r Chem. Biol.	nanodroplets as a 4(12):961-968
	Applicant NA APPLICATION (Use several theese of frecessory) U.S. PATENT DOCUMENTS U.S. PATENT DOCUMENTS Filing Date February 11, 1999 FOREIGN PATENT DOCUMENTS Translation YES NO 1. 03/2097 WO 97/35035 Nicolette OTHER DOCUMENTS OTHER DOCUMENTS Alexander-Miller et al., "Selective expansion of high-or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy" PNAS USA 93(9):4102-4107 (1996). 3. Bloom et al., "Identification of tyrosine-related protein 2 as a tumor rejection antigen for the B16 melanoma" J. Exp. Med. 185(3):453 (1997). 4. Borchardt et al., "Small molecule-dependent genetic selection in stochastic nanodroplets as a means of detecting protein-ligand interactions on a large scale" Chem. Biol. 4(12):961-96. 5. Bouchard et al., "Molecular characterization of a human tyrosinase-related-protein-2 cDNA. Patterns of expression in melanocytic cells" Eur. J. Biochem. 219(1-2):127-134 (1994). 6. Colaco, "Why are dendritic cells central to cancer immunotherapy?" Mol. Med. Today:14-17 (Journary 1999). 7. Gish et al., "Identification of protein coding regions by database similarity search" Nature Genetics 3:266-273 (1993). 8. Kawakami et al., "Identification of a human melanoma antigen recognized by autologous T cells infiltrating into tumor" PNAS USA 91(9):3515-3519 (1994). 10. Lindauer et al., "The molecular basis of cancer immunotherapy by cytotoxic T lymphocytes" J. Mol. Med. 76:32-47 (1998). DATE CONSIDERED: MINNER: Initial if cliation considered, whether or not the citation conforms with MPER 600. Draw lite to the considered in the Matter of the part of the							
INFORMATION DISCLOSURE CITATION (Use several sheets of necessary) U.S. PATENT DOCUMENTS U.S. PATENT DOCUMENTS Filing Date February 11, 1999 Group Art Unit 1588 Group A	1ed. Today:14-17							
		8.	recognized	et al., "Cloning of by autologous T ca	the ge	ene coding for a safiltrating into tur	shared huma nor" PNAS	an melanoma USA 91(9):3
	9.	municating	et al., "Identification lymphocytes assoc	on of a	a human melanor with in vivo tume	ma antigen or rejection	recognized b	y tumor- 1 91:6458-6462
	Doctate Namber 1997/2006/300 Application Number 0997/85437 Applicant Charles A NICOLETTE U.S. PATENT DOCUMENTS U.S. PATENT DOCUMENTS For Date Document No. Name Class Subclass Filing Date Filing Date February 11, 1999 FOREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS Examiner Ref. Date Document No. Country Class Subclass Translation YES NO. 1. 03/20/97 WO 97/35035 Nicolette OTHER DOCUMENTS Translation YES NO. 1. 03/20/97 WO 97/35035 Nicolette OTHER DOCUMENTS Translation YES NO. 1. 03/20/97 WO 97/35035 Nicolette OTHER DOCUMENTS Translation YES NO. 1. 03/20/97 WO 97/35035 Nicolette OTHER DOCUMENTS Translation YES NO. 1. 03/20/97 WO 97/35035 Nicolette OTHER DOCUMENTS Translation YES NO. 1. 03/20/97 WO 97/35035 Nicolette OTHER DOCUMENTS Translation YES NO. 1. 03/20/97 WO 97/35035 Nicolette OTHER DOCUMENTS Translation YES NO. 1. 03/20/97 WO 97/35035 Nicolette OTHER DOCUMENTS Translation YES NO. 1. 03/20/97 WO 97/35035 Nicolette OTHER DOCUMENTS Translation YES NO. 1. 03/20/97 WO 97/35035 Nicolette OTHER DOCUMENTS Translation YES NO. 1. 03/20/97 WO 97/35035 Nicolette OTHER DOCUMENTS Translation YES NO. 1. 03/20/97 WO 97/35035 Nicolette OTHER DOCUMENTS Translation YES NO. 1. 03/20/97 WO 97/35035 Nicolette OTHER DOCUMENTS Translation YES NO. 1. 03/20/97 WO 97/35035 Nicolette OTHER DOCUMENTS Translation YES NO. 1. 03/20/97 WO 97/35035 Nicolette OTHER DOCUMENTS Translation Translation of protein coletage author, title, Date, Pertnent Pages, Extended to the College Action of the College	T lymphocytes"						
WO	11.	Pardoll, "C	ancer vaccines" No	ature	Med. Vaccine Su	upp. 4(5):52	5-531 (May	1998).
								
			~ A		<u> </u>		3)18/	'9V
EXAMINI conformat	EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.						citation if not in	

			Sheet 2 of 2
NFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary) OTHER niner Ref. No. 12. Rosenberg et al., "Immunologic the treatment of patients with m 13. Salgaller et al. "Recognition of peripheral blood lymphocytes s 55:4972-4979 (1995). 14. Schena et al., "Parallel human g 1000 genes" PNAS USA 93:100 15. Shepherd et al., "Preparation an with the P1 cloning system" P1 16. Tam, "Synthetic peptide vaccinantigenic peptide system" PNA 17. Türeci et al., "Serological analy implications" Mol. Med. Today 18. Zhai et al., "Cloning and charact the human melanoma antigens in Inc. 19. Zügel et al., "Termination of pe	Docket Number 159792006300	Application Number 09/249,272	
ITAMS	ON DISCLOSURE CITATION	Applicant	07(920/0
		Charles A. 1	NICOLETTE
Docket Number 159792006300 Application Number 09728972	Group Art Unit 1648 644		
	OTHER D	OCUMENTS (includin	g author, title, Date, Pertinent Pages, Etc.)
	Title		·
12.	Rosenberg et al., "Immunologic an the treatment of patients with meta-	d therapeutic evaluation of a s static melanoma" Nature Med	synthetic peptide vaccine for d. 4(3):321-327 (1998).
13.	Salgaller et al. "Recognition of mu peripheral blood lymphocytes stime	Itiple epitopes in the human m	nelanoma antigen on 100 by
14.	Schena et al., "Parallel human geno 1000 genes" PNAS USA 93:10614	ome analysis: Microarray-bas -10619 (1996).	ed expression monitoring of
15.	Shepherd et al., "Preparation and so with the P1 cloning system" PNAS	creening of an arrayed human USA 91:2629-2633 (1994).	genomic library generated
16.	Tam, "Synthetic peptide vaccine de antigenic peptide system" PNAS U	esign: Synthesis and propertie ISA 85:5409-5413 (1998).	es of a high-density multiple
17.	Türeci et al., "Serological analysis implications" Mol. Med. Today 3(8)	of human tumor antigens: Mo 3):342-349 (August 1997).	plecular definition and
18.	Zhai et al., "Cloning and characteri the human melanoma antigens MA	Charles A. NICOLETTE Filing Date Februaury 11, 1999 Group Art Unit-1648 CCUMENTS (including author, title, Date, Perting the therapeutic evaluation of a synthetic peptide voltatic melanoma" Nature Med. 4(3):321-327 (1) tiple epitopes in the human melanoma antigen galated in vitro with synthetic peptides" Cancer me analysis: Microarray-based expression mort 10619 (1996). Treening of an arrayed human genomic library galaxy 91:2629-2633 (1994). Sign: Synthesis and properties of a high-density SA 85:5409-5413 (1998). Of human tumor antigens: Molecular definition (1):342-349 (August 1997). Pation of the genes encoding the murine homology are all tolerance to a T cell epitope by heteroclific eral tolerance to a T cell epitope by heteroclific	he murine homologues of 20(1):15-25 (1997).
Docket Number 159792006300 Application Number 0972492172 Applicant Charles A NICOLETTE Filing Date Februaury 11, 1999 Group Art Unit-1648 OTHER DOCUMENTS (Including author, title, Date, Pertinent Pages, Ed the treatment of patients with metastatic melanoma" Nature Med. 4(3):321-327 (1998). 13. Salgaller et al. "Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides" Cancer Res. 55:4972-4979 (1995). 14. Schena et al., "Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes" PNAS USA 93:10614-10619 (1996). 15. Shepherd et al., "Preparation and screening of an arrayed human genomic library generated with the P1 cloning system" PNAS USA 91:2629-2633 (1994). 16. Tam, "Synthetic peptide vaccine design: Synthesis and properties of a high-density multiple antigenic peptide system" PNAS USA 85:5409-5413 (1998). 17. Türeci et al., "Serological analysis of human tumor antigens: Molecular definition and implications" Mol. Med. Today 3(8):342-349 (August 1997). 18. Zhai et al., "Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100" J. Immunol. 20(1):15-25 (1997).			
	RMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary) OTHER DOCUMENTS (including pate Februaury 11, 1999) It is a compared to a compared pate of a second pate of a secon		

EXAMINER:

DATE CONSIDERED:

COPY OF PAPERS **ORIGINALLY FILED**

1

PTO/SB/08B (10-01)

arough 10/31/2002, OMB 0651-0031 Approved for u.

	Complete if Known			
ubstitute for form 1449B-PTO	Application Numb r	09/920,480		
INFORMATION DISCLOSURE	Filing Date	August 1, 2001		
STATEMENT BY APPLICANT	First Named Inv nt r	Charles A. NICOLETTE		

1644

🖫 (use as many sheets as necessary)

STATEMENT BY APPLICANT

Sheet

Examiner's

Signature

Examiner Name Not Yet Assigned M DIR **Attomey Docket Number** GZ 2063.10

-	·	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		7
xaminer Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T²	
MO	1	JUNGBLUTH, A. et al. "Expression of melanocyte-associated markers gp-100 and Melan-A/MART-1 in angiomyolipomas" Virchows Arch. (1999) 434:429-345		
	_ 2	RINGHOFER, M. et al. "Quantitative assessment of the expression of melanema associated antigens	 	1
		by non-competitive reverse transcription polymerase chain reaction" Int'l J. Oncol. (2001) 19:983-989		Ή.
	3	de VRIES, T.J. et al. "Heterogeneous expression of immunotherapy candidate proteins gp100, MART-	_	1
	Weller of a replaced makes.	1, and tyrosinase in human melanoma cell lines in the human melanocytic lesions" Cancer Res: (August 1, 1997) 57:3223-3229		-
		DECE	11 /	L
		RECE	IA	F
		AUG 2 S	201	2
		TECH CENTER	100/	ļ,
		TEOTIVENTEN	1001	114
	-			
	-+			
			1	

Art Unit

Date

Considered

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.